论文部分内容阅读
正在巴黎举行的第14届欧洲高血压学会年会(6月13日-17日)刚刚公布了具有里程碑意义的VALUE试验结果。该结果将同时发表于最新一期的Lancet杂志上。VALUE试验的主要研究者-著名高血压研究学者,美国密歇根大学的Stevo Julius教授以及前美国高血压学会主席Michael Weber教授向与会者介绍了VALUE试验的结果,并对其结果进行了精辟独到的分析,本文根据会议的主要内容整理报道,以使国内医生及时了解该试验的最新结果。 VALUE试验是迄今为止最大规模的抗高血压治疗研究之一,包括333例中国患者在内的共15,313例高危高血压患者参与随机分组。研究的主要目的是验证在血压控制相同的情况下,缬沙坦(代文)比氨氮地平能更好地降低心源性死亡率及发病率(主要终点)以及降低心肌梗死、脑卒中、心力表竭和新发糖尿病的发生率。
The 14th annual meeting of the European Society of Hypertension (June 13-17) in Paris has just released the landmark VALUE trial. The results will also be published in the latest issue of Lancet magazine. The leading investigators of the VALUE trial - renowned hypertensive researchers, Professor Stevo Julius of the University of Michigan and Professor Michael Weber, former chairman of the American Society of Hypertension, introduced the results of the VALUE trial and gave an insightful analysis of the results , This article organizes the report according to the main content of the meeting, in order to make domestic doctor keep abreast of the latest results of this experiment. The VALUE trial is by far one of the largest antihypertensive treatment studies involving a total of 15,313 high-risk hypertensive patients in 333 Chinese patients randomized. The primary goal of the study was to verify that valsartan (dhyogeneic) better reduces cardiac mortality and morbidity (primary end point) and reduces MI, stroke, and heartbeat than ammonia-azepine for the same control of blood pressure Exhaustion and the incidence of new onset diabetes.